Tecentriq Hybreza Injection
NDC Package 50242-933-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) injection is tECENTRIQ HYBREZA is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients. This formulation utilizes a injection delivery system. Marketed by Genentech, Inc., this product is identified by NDC 50242-933 and is authorized under FDA application BLA761347.

Identification & Billing

NDC Package Code
50242-933-01
Package Description
1 VIAL, SINGLE-DOSE in 1 BOX / 15 mL in 1 VIAL, SINGLE-DOSE
Product Code
50242-933
11-Digit Billing Format
50242093301
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 2693892 - atezolizumab-hyaluronidase-tqjs 1875 MG / 30,000 UNT in 15 ML Injection
  • RxCUI: 2693892 - 15 ML atezolizumab-tqjs 125 MG/ML / hyaluronidase-tqjs 2000 UNT/ML Injection
  • RxCUI: 2693892 - atezolizumab-hyaluronidase-tqjs 1875 MG / 30,000 UNT per 15 ML Injection
  • RxCUI: 2693899 - Tecentriq Hybreza 1875 MG / 30,000 UNT in 15 ML Injection
  • RxCUI: 2693899 - 15 ML atezolizumab-tqjs 125 MG/ML / hyaluronidase-tqjs 2000 UNT/ML Injection [Tecentriq Hybreza]

Clinical Specifications

Proprietary Name
Tecentriq Hybreza
Non-Proprietary Name
Atezolizumab And Hyaluronidase-tqjs
Substance Name
Atezolizumab; Hyaluronidase (human Recombinant)
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
Pharmacologic Class
Usage Information
TECENTRIQ HYBREZA is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.

Regulatory & Marketing

Labeler Name
Genentech, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761347
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
09-12-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J9024
Source: ASP
Inj atezolizumb 5mg hya-tqjs
HCPCS Dosage 5 MG
Units / Pkg 375

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (50242-933). Click a package code to view its specific billing and regulatory data.

50242-933-86
1 VIAL, SINGLE-DOSE in 1 BOX / 15 mL in 1 VIAL, SINGLE-DOSE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50242-933-01 identifies a specific commercial package of 1 vial, single-dose in 1 box / 15 ml in 1 vial, single-dose of Tecentriq Hybreza, a human prescription drug labeled by Genentech, Inc.. This injection is formulated for subcutaneous use and contains atezolizumab; hyaluronidase (human recombinant) as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Genentech, Inc. on September 12, 2024. The current certification is valid through December 31, 2027.

How is this Genentech, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50242093301. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
50242-933-01
11-Digit CMS (5-4-2)
50242-0933-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.